Highlights Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
2.355 ^USD	+20.15%		+3.29%	-21.76%

05-06	Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	Omega Therapeutics CFO Joshua Reed to Depart	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	04-09	CI
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	03-28	MT
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
North American Morning Briefing : Investors -2-	03-21	DJ
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Novel Therapeutic for Obesity Management	01-05	CI
Novo Nordisk Collaborates With Omega Therapeutics, Cellarity on Cardiometabolic Diseases Research	01-04	MT
Novo Nordisk Signs Research Deals With Omega Therapeutics, Cellarity	01-04	MT
Omega Therapeutics, Inc. Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis	11-13	CI
Omega Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC	16/10/23	CI
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial	26/09/23	CI
Omega Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Omega Therapeutics, Inc. Enter into A Shared Space Arrangements	13/07/23	CI
OMEGA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	04/05/23	AQ
Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Omega Therapeutics Signs Clinical Supply Deal With Roche to Evaluate Potential Cancer Combination Therapy	30/03/23	MT
Omega Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma	30/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Highlights

Filters